GlassScriptPhysician profile
Lori Tovar
NPI 1255199410
$2,294.20
in general payments reported to CMS, 2019-2025
13 companies · $1,305 in 2025
The $1,305 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $989 · 2025: $1,305.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,210 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,210.20 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $738.94 | 2024-2025 | Tremfya, Stelara, Simponi |
| Abbvie INC. | $391.62 | 2024-2025 | |
| Melinta Therapeutics, LLC | $214.75 | 2024-2025 | Rezzayo, Kimyrsa, Orbactiv |
| Viiv Healthcare Company | $197.28 | 2024-2025 | Cabenuva, Rukobia, Apretude |
| Takeda Pharmaceuticals U.S.A., INC. | $179.78 | 2024-2025 | Entyvio, Eohilia |
| Gilead Sciences, INC. | $163.17 | 2024 | Epclusa |
| Madrigal Pharmaceuticals | $109.42 | 2025 | Rezdiffra |
| Ardelyx, INC. | $81.25 | 2024 | Ibsrela |
| Napo Pharmaceuticals INC | $76.70 | 2024-2025 | Mytesi |
| Ipsen Biopharmaceuticals, INC | $51.26 | 2025 | Iqirvo |
| Shionogi INC | $38.95 | 2024-2025 | Fetroja |
| Merck Sharp & Dohme LLC | $28.16 | 2025 | Zerbaxa, Prevymis |
| Paratek Pharmaceuticals, INC. | $22.92 | 2024 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Tovar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.